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Great hope has been given to micronutrients as anticancer agents, since they present natural compounds with beneficial effects for
normal cells and tissues. One of these is vitamin E (VE), an antioxidant and an essential component of biological membranes and
circulating lipoproteins. In spite of a number of epidemiological and intervention studies, little or no correlation between VE intake
and incidence of cancer has been found. Recent reports have identified a redox-silent analogue of VE, a-tocopheryl succinate (a-
TOS), as a potent anticancer agent with a unique structure and pharmacokinetics in vivo. a-TOS is highly selective for malignant cells,
inducing them into apoptotic death largely via the mitochondrial route. The molecule of a-TOS may be modified so that analogues
with higher activity are generated. Finally, a-TOS and similar agents are metabolised to VE, thereby yielding a compound with a
secondary beneficial activity. Thus, a-TOS epitomises a group of novel compounds that hold substantial promise as future anticancer
drugs. The reasons for this optimistic notion are discussed in the following paragraphs.
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VITAMIN E (VE) IS A POOR ANTICANCER AGENT
Numerous epidemiological and intervention studies tested the
possibility that VE suppresses cancer (see e.g. Albanes et al, 1996,
2000; Heinonen et al, 1998; Heart Protection Study Collaborative
Group, 2002). The idea has been attractive, as VE is a
micronutrient with high antioxidant activity. To a certain degree,
the level of VE can be manipulated by dietary supplementation. As
the hepatic system prevents both VE hyper- and hypovitaminosis,
maintaining the circulating/tissue levels of VE within a narrow
margin, pathologies associated with too much or too little VE, are
rare. Therefore, it is apparent that diseases linked to VE deficiency
will only occur in association with infrequent syndromes of
impairment of VE intake and its maintenance, such as abetalipo-
proteinaemia or the familial isolated VE deficiency syndrome. On
the other hand, given the relatively narrow margin between
minimal and maximal VE levels in circulating lipoproteins and in
tissues, there is only a limited scope for VE manipulation by
intervention therapy. Hence, it is not surprising that little or no
association between disease incidence, including neoplasia, and VE
intake has been repeatedly observed (Albanes et al, 1996, 2000;
Heart Protection Study Collaborative Group, 2002). Attempts to
find a correlation between VE supplementation and pathology may
have failed as, following VE ingestion, its level raises only
transiently, the ‘excess’ VE being efficiently removed from the
body by the hepatic system armed with the saturable a-tocopherol
(a-TOH) transfer protein (Brigelius-Flohe et al, 2002).
a-TOCOPHERYL SUCCINATE (a-TOS) IS AN
ANTICANCER VE ANALOGUE DUE TO ITS
APOPTOGENIC ACTIVITY
Probably, the main reason why VE as such exerts little or no
anticancer effect may be due to its biological activity, since it is a
redox-active substance, which does not cause, unlike many
anticancer agents, apoptosis of malignant cells (Neuzil et al,
1999). This premise, however, has been found for semisynthetic
analogues of VE, as documented in a number of recent reports for
a-TOS (Fariss et al, 1994; Neuzil et al, 1999; Pussinen et al, 2000;
Neuzil et al, 2001a–c; Yu et al, 2001). The mechanism by which a-
TOS kills cancer cells is not completely understood. It has been
shown that this occurs by inducing apoptosis in malignant cells
primarily by mitochondrial destabilisation (Alleva et al, 2001;
Kogure et al, 2001; Neuzil et al, 2001c; Weber et al, 2003), a process
amplified by the modulation of signalling pathways (Qian et al,
1997; Neuzil et al, 2001c; Yu et al, 2001). Mitochondrial
destabilisation is caused, most likely, by the detergent-like activity
of a-TOS (Neuzil et al, 2002). That is, a-TOS comprises a
hydrophobic phytyl chain (hydrophobic domain) and the charge-
able succinyl group (functional domain), separated by the bulky
tocopheryl moiety (signalling domain) (Neuzil, 2002). It is possible
that a-TOS-induced apoptosis also involves lysosomal destabilisa-
tion by the agent, an action running parallel to and/or amplifying
mitochondrial disruption (Neuzil et al, 2002). a-TOS may signal
along several pathways. It has been shown that, due to its a-
tocopheryl moiety, the agent activates protein phosphatase-2A
that, in turn, inhibits protein kinase C (PKC). This leads to
hypophosphorylation of the antiapoptotic protein bcl-2, with
ensuing mitochondrial labilisation (Neuzil et al, 2001c). This
pathway itself does not cause apoptosis by the VE analogues, but
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mitochondria, since b-, g- and d-TOS lacking the PKC inhibitory
activity are less apoptogenic than the a-analogue (Neuzil et al,
2001c; Birringer et al, 2003). Other pathways that are likely
implicated in apoptosis induced by a-TOS include deregulation of
the c-jun/AP-1 (Qian et al, 1997) and the TGF-b pathway (Turley
et al, 1995), as well as inhibition of the cell cycle transition (Turley
et al, 1997a,b).
The strong apoptogenic activity of a-TOS translates to its
anticancer efficacy, as shown in preclinical models. Malafa and co-
workers have demonstrated the inhibition of breast cancer in a
mouse model (Malafa and Neitzel, 2000), as well as suppression of
melanomas (Malafa et al, 2002a) and colon cancer metastasis
(Barnett et al, 2002). We have shown that the VE analogue
suppressed colon cancer in an athymic mouse model, and its
antineoplastic effect was much higher than that of a-TOH, which
exerted only minor, nonsignificant cancer suppression (Weber
et al, 2002). The great superiority of a-TOS over a-TOH in cancer
inhibition is due to the fact that, while both agents inhibit
proliferation of malignant cells in the xenografts, only a-TOS
causes their apoptosis (Weber et al, 2002) (Figure 1A). Another
possible mode of antineoplastic activity of VE succinate is that it
appears to be antiangiogenic (Malafa et al, 2002b). This notion
follows also from findings that a-TOS causes apoptosis of
proliferating, but not growth-arrested endothelial cells (Neuzil
et al, 2002), and inhibits the expression of angiogenic cytokines,
such as VEGF (Malafa and Neitzel, 2000). We have recently
observed suppression of blood vessel sprouting by a-TOS in a
mouse model of neonatal retinal neovascularisation (Neuzil et al,
unpublished).
PROAPOPTOTIC/ANTINEOPLASTIC ACTIVITY OF VE
ANALOGUES IS STRUCTURE-DEPENDENT
The reason why a-TOS is proapoptotic while a-TOH does not
possess this activity (in fact, a-TOH is antiapoptotic) has been
investigated in considerable detail over the last few years.
Importantly, Fariss et al (1994) showed that the cell-killing activity
of a-TOS requires an intact molecule of the agent. They reported
that the ester, which can be hydrolysed by some cells to free VE,
has identical activity as its ether counterpart that is not
hydrolysable. We have explored in more detail the structure–
function relationship of these agents and found several interesting
features (Birringer et al, 2003). Firstly, the presence of the phytyl
group was essential for the activity, since the succinyl ester of
Trolox was inactive. This can be explained by the fact that such a
molecule is highly water soluble, therefore does not associate with
lipid membranes. As mentioned earlier, lowering the number of
methyl substituents on the tocopheryl moiety decreased the
proapoptotic efficacy. Replacement of the succinyl group by
an uncharged group, for example acetate, or its methylation,
obliterated the proapoptotic activity. On the other hand, ester-
ification of a-TOH with other dicarboxylic acids modulated the
apoptogenic activity as follows: esters with higher number of
carbons had lower activity than a-TOS, while esterification with
unsaturated dicarboxylic acids, such as maleyl acid, highly
enhanced the activity. Thus, a-tocopheryl maleate (a-TOM) is
the most apoptogenic VE analogue tested to date (Birringer et al,
2003).
The unique structural features of agents like a-TOS probably
make them selective for malignant cells (Neuzil et al, 2001b). While
speculative at present, it is possible that the surprisingly high
toxicity of a-TOS towards cancer cells and tissues is due to their
persistence in such cells in the original form, while normal cells,
including fibroblasts (Roberg et al, 1999), cardiac myocytes
(Roberg and Ollinger, 1998), hepatocytes (Tirmenstein et al,
1999) and intestinal epithelial cells (Borel et al, 2001), are all
capable of its hydrolysis to a-TOH. On the other hand, malignant
cells, such as the human T lymphoma, malignant mesothelioma
and colon cancer cells exert only a very low hydrolytic capacity
towards a-TOS (Neuzil et al, unpublished). Another reason for the
selectivity of a-TOS may result from its physicochemical proper-
ties. The VE analogue is a weak acid with a low pKa value.
Therefore, at the neutral pH of normal tissue interstitium, majority
of a-TOS exists in the charged, deprotonated state. Since there are
no known transporters of a-TOS, it can be expected that it will
cross the plasma membrane at a low rate. On the other hand, the
acidic pH of the tumour interstitium causes protonation of a
substantial portion of the total a-TOS, facilitating its free diffusion
into the cell. In favour of this hypothesis, lowering the pH of the
cell culture medium enhanced the killing of cancer cells by a-TOS,
but not by g-tocotrienol, an apoptogenic VE analogue that cannot
be deprotonated (Neuzil et al, 2002). This is consistent with the
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Figure 1 a-TOS inhibits colon cancer (A), and is converted to the
redox-active a-TOH (B) (adapted from Weber et al, 2002). Nude mice
with colon cancer xenografts were treated with the vehicle (control), a-
TOH or a-TOS, by intraperitoneal injection of 100nmol of the drug, every
second day for 10 days. In the end, the tumour size was estimated (A) and
the mouse plasma was analysed for the level of a-TOH (B). (C) Bases of
the hypothesis are presented in this communication. After reaching the
circulation, a VE analogue (epitomised in our studies by a-TOS) binds to
circulating lipoproteins (LP), which carry it to the microvasculature, where it
kills cancer cells (this is the ‘provitamin E effect’). Lipoproteins with bound
a-TOS are cleared in the liver, where nonspecific esterase (NE) very
efficiently cleaves it into a-TOH. The newly generated a-TOH is in part
excreted in the bile, in part bound to the saturable a-tocopheryl-transfer
protein (a-TTP), which inserts it into nascent very low-density lipoprotein.
In this way, the provitamin E is converted to VE, which increases the
antioxidant defences and acts as an immunosuppressive agent.
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anticancer agents due to their preferential uptake by tumour tissue
cells (Gerweck et al, 1999; Kozin et al, 2001).
It is therefore possible to modify the structure of VE analogues
so that agents with higher proapoptotic activity and selectivity for
malignant cells are generated. Thus, this group of compounds
provides a unique opportunity for further structure–activity
studies.
VE ANALOGUES AS ADJUVANTS FOR CANCER
IMMUNOTHERAPY
A commonly used practice in tumour treatment is to combine
several anticancer agents with different modes of action. The
reasons for this approach are both maximising the apoptotic
potential of the cell, overcoming resistance to one of the agents by
utilising complementing proapoptotic pathways and lowering the
doses of the individual drugs to suppress the potential secondary
deleterious effects of the treatment. From this point of view, a-TOS
has shown substantial promise.
There are several reports documenting that the VE analogue
potentiates cancer cells killing by the immunological apoptogen
Fas, viz by mobilising the Fas receptor from the cytosol to the
plasma membrane; this has been shown for both prostate and
breast cancer cells (Turley et al, 1997; Yu et al, 1999). These
findings suggest that a-TOS has the propensity to boost the
immune system to enhance cancer surveillance. While the Fas
ligand itself is highly cytotoxic, the TNF-related apoptosis-
inducing ligand (TRAIL) is selective for cancer cells (Bonavida
et al, 1999). Therefore, the reports that a-TOS can potentiate
cancer cells to killing by TRAIL may be of pharmacological
importance. This has been shown for both colon cancer (Weber
et al, 2002) and mesothelioma cells (Neuzil et al, unpublished) as
well as for T lymphoma cells (Dalen and Neuzil, 2003). One
mechanism by which a-TOS sensitises cells to killing by TRAIL is
that the two agents use different pathways of apoptotic signalling,
that is, a-TOS activates the distant, mitochondrial pathway, while
TRAIL acts through the proximal, receptor-mediated route (Weber
et al, 2002). Moreover, the in vitro cooperative killing of colon
cancer cells by the two agents has also been reported for the
suppression of colon cancer in a preclinical model (Weber et al,
2002). Another possible mechanism of synergism and/or coopera-
tion between TRAIL and a-TOS is the inhibition of activation of
the nuclear factor-kB (NFkB). This transcriptional factor controls
the expression of a number of prosurvival genes, and is activated
in some cancer cells due to TRAIL crosslinking of one or more of
its cognate receptors (Degli-Esposti et al, 1997; Bernard et al,
2001). a-TOS has been shown to suppress the activation of NFkB
(Suzuki and Packer, 1993; Erl et al, 1997), and we have shown that
this may be due to the induction of proapoptotic signalling leading
to caspase-3 activation that, in turn, cleaves the NFkB subunit p65
(Neuzil et al, 2001a). A recent finding revealing that the
suppression of NFkB activation by a-TOS, following exposure to
TRAIL, sensitises T lymphoma cells to killing by the immunolo-
gical apoptogen (Dalen and Neuzil, 2003), may be of pharmaco-
logical interest. Finally, a-TOS can sensitise cancer cells by
upregulation of the TRAIL death receptors, as in the TRAIL-
resistant mesothelioma cells (Neuzil et al, unpublished).
THE PROMISE OF CANCER THERAPY BY VE
ANALOGUES IS BASED ON PRECLINICAL STUDIES
Thus far, there have been very few studies on the anticancer effects
of VE analogues in vivo. This is surprising, since the toxic effects of
a-TOS towards malignant cells have been known since the early
1980s (Prasad and Edwards-Prasad, 1982; Prasad et al, 2003).
Probably, the strongest evidence suggesting the potential use of VE
analogues in the treatment of humans with neoplastic disease
comes from the laboratory of Malafa. They first showed that a-TOS
promoted beast cancer dormancy in an immunocompromised
mouse (Malafa and Neitzel, 2000) and, later on, also melanoma
dormancy (Malafa et al, 2002b); in both cases, inhibition of
angiogenesis via suppression of VEGF signalling by a-TOS was
suggested as the underlying mechanism, pointing to an indirect
effect of the VE analogue on cancer growth. The acute effect of a-
TOS has been shown by the same group for experimental
melanoma (Malafa et al, 2002a) and colon cancer liver metastases
(Barnett et al, 2002), and similar suppression of experimental
melanomas has been observed by others (Kogure et al, 2003). In
these experiments, the main mode of action of a-TOS was ascribed
to its apoptogenic effect on the cancer cells. We have reported a
significant inhibition of colon cancer growth in immunocompro-
mised mice treated with a-TOS and its superiority to a-TOH
(Neuzil et al, 2001c; Weber et al, 2002), and have also shown its
cooperativity in vivo with the immunological apoptogen TRAIL
(Weber et al, 2002). Finally, our recent studies revealed that a-TOS
strongly enhances the survival of immunocompromised mice with
experimental peritoneal mesothelioma, a thus far incurable type of
human neoplastic disease (Neuzil et al, unpublished data).
Although these studies show a strong promise, there are certain
drawbacks that need to be solved before a-TOS and similar
compounds its possible application to humans. These compounds
are esters of VE, and as such, are fully hydrolysed during the
intestinal uptake following oral administration. Therefore, intra-
venous application is required. This can be overcome by
generating analogues where the ester bond is replaced by an ether
bond (Fariss et al, 1994), since ethers are not subject to enzymatic
hydrolysis. An ether VE analogue has been recently reported as
being highly effective in suppressing mammary tumours and lung
metastases in syngeneic mice (Lawson et al, 2003). While this
approach makes it possible to administer VE analogues orally, it
jeopardises the most intriguing feature of the analogues based on
VE esters in that the ether compounds are not broken down to the
free VE (see below). Notwithstanding, the ether analogues of VE
make it possible to administer the drugs orally, which has a clear
advantage over intravenous application of the ester compounds,
and we and others are pursuing this option as well.
PHARMACOKINETICS OF VE ESTERS – A NOVEL
PROVITAMIN-TO-VITAMIN CONVERSION MODEL
Perhaps, the most exciting aspect of the potential use of
compounds like a-TOS, a pro-VE, follows from its pharmacoki-
netics. After infusion into the circulatory system, the VE analogue
associates with circulating lipoproteins (Kayden and Traber, 1993;
Pussinen et al, 2000). This carrier delivers it to the microvascu-
lature of the tumour. Since there is a constant exchange of
hydrophobic molecules between lipoproteins and the peripheral
tissue, a-TOS can traverse to malignant cells, where it induces
apoptosis (Neuzil, 2002). Due to rapid turnover of lipoproteins
(Traber et al, 1994), a-TOS is eventually cleared in the liver.
Hepatocytes have a high activity of nonspecific esterases that
cleave the VE ester to a-TOH. Further, during processing of
lipoproteins in the liver cells, the natural stereoisomer of a-TOH
associates with the highly specific a-TOH-binding protein, which
inserts this most active form of VE into nascent very low-density
lipoprotein that is, in turn, resecreted into circulation via the
hepatic vein (Terasawa et al, 2000). In this way, following
hydrolysis of a-TOS, the circulation is enriched with VE. There-
fore, the pro-VE, a-TOS and similar compounds (Birringer et al,
2003) are converted to the redox-active VE with additional
beneficial activity (Neuzil, 2002), including increased protection
against oxidative stress and immunosuppressive activity (Li-
Weber et al, 2002). Moreover, several reports showed that a-TOS
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toxic agents, including adriamycin (Dominguez-Rodriguez et al,
2001; Fariss et al, 2001).
Based on direct and circumstantial evidence and on theoretical
considerations, a novel hypothesis is proposed explaining why VE
is inefficient as an anticancer agent and why its analogues may be
deemed as potent anticancer drugs (Figure 1B). According to this
hypothesis, VE succinate and similar analogues (in general, esters
of VE with a free carboxylic group) induce apoptosis selectively in
cancer cells while VE itself is not apoptogenic. Due to multiple
activities, including apoptosis induction and sensitisation of
cancer cell killing by other agents, VE succinate and its analogues
inhibit cancer growth. Following the anticancer activity discharge,
the pro-VE is converted to the redox-active VE, part of which
enters the circulation.
Therefore, it is imperative to test this hypothesis, as it is believed
that VE analogues, epitomised by a-TOS, represent an exciting
group of novel anticancer agents of potential high pharmacological
importance.
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